18F-FDG PET/CT纳入肝细胞癌肝移植标准的趋势与价值

蒲朝煜; 王剑杰; 周里; 陈虹

doi:10.3969/j.issn.1001-5256.2020.02.041

18F-FDG PET/CT纳入肝细胞癌肝移植标准的趋势与价值

DOI: 10.3969/j.issn.1001-5256.2020.02.041

2. 河北医科大学附属河北燕达医院核医学科
3. 北京清华长庚医院肝胆胰中心

详细信息

中图分类号: R730.44;R735.7
计量
- 文章访问数: 922
- HTML全文浏览量: 26
- PDF下载量: 182
- 被引次数: 1
出版历程
- 收稿日期: 2019-09-25
- 出版日期: 2020-02-20

The trend and value of18F-FDG PET/CT included in the criteria for liver transplantation in hepatocellular carcinoma

Department of Nuclear Medicine,Beijing Rimag Medical Imaging Diagnosis Center

摘要

摘要:
肝移植是治疗肝细胞癌（HCC）的有效方法,为降低HCC肝移植术后可能出现较高肿瘤复发率,有学者率先提出著名的Milan标准。但该标准过于严格,部分患者因其肿瘤病变较大或多个结节,虽其生物行为相对"温良",也被排除在等待肝移植名单之外,随之世界各地出现了众多的"扩大Milan版标准"。HCC组织病理学的微血管侵犯（MVI）、肿瘤组织低分化与HCC肝移植术后较高复发率有显著相关性。复习总结了近年来国内外18氟-脱氧葡萄糖(18F-FDG) PET/CT在HCC肝移植方面的应用文献,发现18F-FDG在HCC病变部位不同的摄取程度,反映了肿瘤组织生物学行为特征即侵袭性的差异;18F-FDG高摄取与HCC病变的MVI、低分化呈正相关;18F-FDG还能敏感、准确地发现HCC肝外转移灶。认为术前18F-FDG PET/CT结果对HCC肝移植预后评估有巨大价值,将其结果纳入HCC肝移植标准是趋势所归,也有望统一"扩大Milan版标准"。建议新的肝移植标准可定义为,原则上遵循Milan标准;...
- 癌,肝细胞 /
- 肝移植 /
- 正电子发射断层显像计算机体层摄影术 /
- 氟脱氧葡萄糖F18
Abstract:
Liver transplantation is an effective method for the treatment of hepatocellular carcinoma( HCC). In order to reduce the high recurrence rate of tumor after liver transplantation for HCC,some scholars put forward the famous Milan criteria. Since the Milan criteria are too strict,some HCC patients with relatively“good biological behavior”and large lesions or multiple nodules are excluded from the waiting list for liver transplantation,and thus a large number of“expanded versions of the Milan criteria”appeared around the world. As for the histopathology of HCC,microvascular invasion( MVI) and poorly differentiated tumor tissue are significantly associated with the high recurrence rate after liver transplantation for HCC. This article reviews and summarizes the articles on the application of18F-FDG PET/CT in liver transplantation for HCC in China and foreign countries and points out that the uptake of18F-FDG in HCC lesions reflects the difference in the biological behavior( i. e.,invasion) of tumor tissue. The intense uptake of18F-FDG is positively correlated with MVI and poor differentiation of HCC. In addition,18F-FDG can detect extrahepatic metastatic lesions sensitively and accurately. Preoperative18F-FDG PET/CT findings have a high value in predicting the prognosis of liver transplantation for HCC,and it is a trend to incorporate such findings into the criteria for liver transplantation in HCC. It is also expected to unify the various expanded versions of the Milan criteria. The new criteria for liver transplantation may be defined as follows: the Milan criteria should be followed in general; as for the patients who do not meet the Milan criteria,liver transplantation can be performed for those who have lesions with negative18F-FDG PET/CT results,without the involvement of major blood vessels or extrahepatic metastasis.
- carcinoma,hepatocellular /
- liver transplantation /
- positron emission tomography computed tomography /
- fluorodeoxyglucose F18

HTML全文

参考文献(26)

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] LEE SM,KIM HS,LEE S,et al. Emerging role of18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma[J]. World J Gastroenterol,2019,25(11):1289-1306.

[3] PANT V,SEN IB,SOIN AS. Role of18F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma[J]. Nucl Med Commun,2013,34(8):749-757.

[4] KORNBERG A,SCHERNHAMMER M,FRIESS H.18F-FDGPET for assessing biological viability and prognosis in liver transplant patients with hepatocellular carcinoma[J]. J Clin Transl Hepatol,2017,5(3):224-234.

[5] MAZZAFERRO V,REGALIA E,DOCI R,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med,1996,334(11):693-699.

[6] LI HB,FU HY,LU TY,et al. Key research advances in liver transplantation in 2017[J]. Ogran Transplantation,2018,9(1):41-50,82.(in Chinese)李海波，符洪源，陆桐宇，等．肝移植领域2017年度重要进展盘点[J]．器官移植，2018,9(1):41-50,82.

[7] YAO FY,FERRELL L,BASS NM,et al. Liver transplantation for hepatocellular carcinoma:Expansion of the tumor size limits does not adversely impact survival[J]. Hepatology,2001,33(6):1394-1403.

[8] MARSH JW,DVORCHIK I,BONHAM CA,et al. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?[J]. Cancer,2000,88(3):538-543.

[9] LEE SG,HWANG S,MOON DB,et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center[J]. Liver Transpl,2008,14(7):935-945.

[10] DUBAY D,SANDROUSSI C,SANDHU L,et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion[J].Ann Surg,2011,253(1):166-172.

[11] MAZZAFERRO V,LLOVET JM,MICELI R,et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria:A retrospective,exploratory analysis[J]. Lancet Oncol,2009,10(1):35-43.

[12] ZHENG SS,WANG K,XU X,et al. Clinical value of Hangzhou Criteria in selection of patients with hepatocellular carcinoma for living donor liver transplantation[J]. Chin J Organ Transplant,2011,32(6):330-333.(in Chinese)郑树森，汪恺，徐骁，等．肝移植治疗肝癌的受者选择杭州标准在亲属活体供肝移植中的应用价值[J]．中华器官移植杂志，2011,32(6):330-333.

[13] FAN J,ZHOU J,XU Y,et al. Indication of liver transplantation for hepatocellular carcinoma:Shanghai Fudan Criteria[J].Natl Med J China,2006,86(18):1227-1231.(in Chinese)樊嘉，周俭，徐泱，等．肝癌肝移植适应证的选择:上海复旦标准[J]．中华医学杂志，2006,86(18):1227-1231.

[14] CHANG XJ,LU YY,RONG GH,et al. Risk factors for vascular invasion of primary liver cancer[J]. J Clin Hepatol,2018,34(5):1038-1041.(in Chinese)常秀娟，陆荫英，荣光华，等．原发性肝癌发生血管侵犯的危险因素分析[J]．临床肝胆病杂志，2018,34(5):1038-1041.

[15] HSU CC,CHEN CL,WANG CC,et al. Combination of FDGPET and UCSF Criteria for predicting HCC recurrence after living donor liver transplantation[J]. Transplantation,2016,100(9):1925-1932.

[16] SUN DW,AN L,WEI F,et al. Prognostic significance of parameters from pretreatment(18)F-FDG PET in hepatocellular carcinoma:A meta-analysis[J]. Abdom Radiol(NY),2016,41(1):33-41.

[17] IJICHI H,SHIRABE K,TAKETOMI A,et al. Clinical usefulness of(18)F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types,hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma[J]. Hepatol Res,2013,43(5):481-487.

[18] WANG YT,ZUO CJ,ZHANG J,et al. Value of Fluorine-18-fluorodeoxyglucose PET/CT examination to predict microvascular invasion of hepatocellular carcinoma[J]. Chin J Dig Surg,2018,17(1):109-115.(in Chinese)王玉涛，左长京，张建，等．18氟-氟代脱氧葡萄糖PET/CT检查预测肝细胞癌微血管侵犯的价值[J]．中华消化外科杂志，2018,17(1):109-115.

[19] KOBAYASHI T,AIKATA H,HONDA F,et al. Preoperative fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for prediction of microvascular invasion in small hepatocellular carcinoma[J]. J Comput Assist Tomogr,2016,40(4):524-530.

[20] BAILLY M,VENEL Y,ORAIN I,et al.18F-FDG PET in liver transplantation setting of hepatocellular carcinoma:Predicting histology?[J]. Clin Nucl Med,2016,41(3):e126-e129.

[21] LIN CY,LIAO CW,CHU LY,et al. Predictive value of18FFDG PET/CT for vascular invasion in patients with hepatocellular carcinoma before liver transplantation[J]. Clin Nucl Med,2017,42(4):e183-e187.

[22] YANG SH,SUH KS,LEE HW,et al. The role of(18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients[J]. Liver Transpl,2006,12(11):1655-1660.

[23] KORNBERG A,WITT U,SCHERNHAMMER M,et al. Combining18F-FDG positron emission tomography with Up-toSeven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma[J]. Sci Rep,2017,7(1):14176.

[24] LEE SD,KIM SH,KIM SK,et al. Clinical impact of18F-fluorodeoxyglucose positron emission tomography/computed tomography in living donor liver transplantation for advanced hepatocellular carcinoma[J]. Transplantation,2015,99(10):2142-2149.

[25] REFAAT R,BASHA MAA,HASSAN MS,et al. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma[J]. Eur Radiol,2018,28(12):5356-5367.

[26] TAKADA Y,KAIDO T,SHIRABE K,et al. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients:A Japanese multicenter study[J]. J Hepatobiliary Pancreat Sci,2017,24(1):49-57.

施引文献